MCID: ORL005
MIFTS: 55

Oral Candidiasis

Categories: Gastrointestinal diseases, Infectious diseases, Oral diseases, Rare diseases, Reproductive diseases
Data Licensing
For inquiries, contact:

Aliases & Classifications for Oral Candidiasis

MalaCards integrated aliases for Oral Candidiasis:

Name: Oral Candidiasis 11 53 14 16 71 75
Thrush 11 75 2
Candidiasis of Mouth 11
Candidiasis, Oral 43
Oral Moniliasis 11
Equine Thrush 71
Thrush, Oral 11
Candidiasis 71
Oral Thrush 63

Classifications:



External Ids:

Disease Ontology 11 DOID:14262
ICD9CM 34 112.0
MeSH 43 D002180
NCIt 49 C28137
SNOMED-CT 68 187006006
ICD10 31 B37.9
UMLS 71 C0006840 C0006849 C1299921

Summaries for Oral Candidiasis

PubMed Health : 63 Oral thrush: Oral thrush is a condition that can be difficult to recognize at first. It is rarely dangerous and not necessarily painful, but can be very unpleasant and greatly affect your quality of life. Oral thrush is caused by types of yeast fungus called Candida that live in the mucous membranes lining your mouth. Its medical name “oral candidiasis” is taken from this fungus. Oral thrush is most often caused by a type of Candida fungus called Candida albicans. Most people have small amounts of Candida on the mucous linings of their mouth without it causing any noticeable problems. But given the right conditions, the fungus can start reproducing very quickly. This often affects people who have serious diseases, and it can also be a side effect of certain types of treatment.

MalaCards based summary: Oral Candidiasis, also known as thrush, is related to candida glabrata and denture stomatitis, and has symptoms including oral manifestations An important gene associated with Oral Candidiasis is DEFB4A (Defensin Beta 4A), and among its related pathways/superpathways are Cytokine Signaling in Immune system and Innate Immune System. The drugs Fluticasone and Nystatin have been mentioned in the context of this disorder. Affiliated tissues include tongue, skin and liver, and related phenotypes are Increased shRNA abundance (Z-score > 2) and immune system

CDC: 2 Candidiasis is an infection caused by a yeast (a type of fungus) called Candida. Candida normally lives inside the body (in places such as the mouth, throat, gut, and vagina) and on skin without causing any problems.1 Sometimes, Candida can multiply and cause an infection if the environment inside the mouth, throat, or esophagus changes in a way that encourages fungal growth. Candidiasis in the mouth and throat is also called "thrush" or oropharyngeal candidiasis. Candidiasis in the esophagus (the tube that connects the throat to the stomach) is called esophageal candidiasis or Candida esophagitis. Esophageal candidiasis is one of the most common infections in people living with HIV/AIDS

Disease Ontology: 11 A candidiasis that involves fungal infection of the mucous membrane of the mouth by Candida species, which is characterized by thick white or cream-colored deposits on inflamed mucosal membranes.

Wikipedia 75 Oral candidiasis: Oral candidiasis, also known as oral thrush among other names, is candidiasis that occurs in the mouth.... more...

Thrush: Candidiasis is a fungal infection due to any type of Candida (a type of yeast). When it affects the... more...

Related Diseases for Oral Candidiasis

Diseases related to Oral Candidiasis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 378)
# Related Disease Score Top Affiliating Genes
1 candida glabrata 31.1 SKAP2 HTN3 APCS
2 denture stomatitis 31.1 ECE1 DEFB4A CLEC7A
3 candidiasis 30.9 SKAP2 LTF IL17RA IL17F IL17A HTN3
4 angular cheilitis 30.9 IL17A CD4 AIRE
5 sjogren syndrome 30.7 LTF CCR6 B2M
6 immune deficiency disease 30.7 IRF8 IL17A CD4 CCR6 B2M APCS
7 psoriasis 11 30.5 IL17RA IL17F IL17A
8 common cold 30.4 IL17A CD4 CCR6
9 viral infectious disease 30.3 IL17A CD4 CCR6 B2M
10 t cell deficiency 30.3 IL17A CD4 CCR6
11 exanthem 30.3 IL17A CD4 CCR6
12 severe covid-19 30.3 IL17A CD4 CCR6
13 vaginitis 30.2 IL17A DEFB4A CD4 CCR6
14 mucormycosis 30.2 CLEC7A CD4 CCR6 CARD9
15 pneumocystosis 30.1 IL17A CLEC7A CD4 CCR6 CARD9
16 human cytomegalovirus infection 30.1 IL17A CD4 CCR6
17 anterior uveitis 30.1 IL17A CD4 CCR6
18 salmonellosis 30.1 IL17A CD4 CCR6
19 psoriasis 30.0 IL17RA IL17F IL17A DEFB4A CD4 CCR6
20 seborrheic dermatitis 30.0 IL17A DEFB4A CD4 CCR6
21 blepharitis 30.0 LTF IL17A CD4 CCR6
22 bacterial pneumonia 30.0 IL17A DEFB4A CD4 CCR6
23 behcet syndrome 30.0 IRF8 IL17F IL17A CD4 CCR6
24 autoimmune disease 29.9 IL17F IL17A CCR6 B2M AIRE
25 cryptococcal meningitis 29.9 IL17A CLEC7A CLEC6A CD4 CCR6
26 spondyloarthropathy 1 29.9 IL17F IL17A CD4 CCR6
27 histoplasmosis 29.8 CLEC7A CLEC6A CD4 CCR6
28 crohn's disease 29.8 LTF IL17F IL17A CD4 CCR6
29 esophageal candidiasis 29.8 IL17A CLEC7A CD4 CCR6 CARD9 AIRE
30 severe combined immunodeficiency 29.8 IL17A IKBKB CD4 CCR6 AIRE
31 combined immunodeficiency 29.8 IL17A IKBKB CD4 CCR6 AIRE
32 cryptococcosis 29.7 IL17A CLEC7A CLEC6A CD4 CCR6 CARD9
33 chronic mucocutaneous candidiasis 29.5 IL17RA IL17F IL17A CLEC7A CLEC6A CD4
34 tinea pedis 29.4 IL17A DEFB4A CLEC7A CLEC6A CD4 CCR6
35 skin disease 29.3 IL17RA IL17F IL17A IKBKB DEFB4A CD4
36 vulvovaginal candidiasis 29.2 IL17RA IL17A ECE1 CLEC7A CLEC6A CCR6
37 dermatophytosis 29.1 IL17F IL17A DEFB4A CLEC7A CLEC6A CD4
38 autoimmune polyendocrine syndrome 29.1 IL17RA IL17F IL17A CLEC7A CD4 CCR6
39 autoimmune polyendocrine syndrome type 1 29.1 IL17RA IL17F IL17A CLEC7A CD4 CCR6
40 fungal infectious disease 28.9 IL17RA IL17F IL17A ECE1 DEFB4A CLEC7A
41 severe combined immunodeficiency, autosomal recessive, t cell-negative, b cell-positive, nk cell-negative 11.1
42 immunodeficiency 104 11.1
43 median rhomboid glossitis 11.1
44 immunodeficiency 32b 11.1
45 t-cell immunodeficiency, congenital alopecia, and nail dystrophy 11.1
46 immunodeficiency 15a 11.1
47 acquired immunodeficiency syndrome 10.6
48 human immunodeficiency virus type 1 10.6
49 stomatitis 10.6
50 leukoplakia 10.5

Comorbidity relations with Oral Candidiasis via Phenotypic Disease Network (PDN): (show all 35)


Acquired Thrombocytopenia Active Peptic Ulcer Disease
Acute Cystitis Acute Kidney Failure
Alzheimer Disease, Familial, 1 Anxiety
Bronchitis Bronchopneumonia
Chronic Pulmonary Heart Disease Conn's Syndrome
Decubitus Ulcer Deficiency Anemia
Dysthymic Disorder Esophageal Candidiasis
Esophagitis Familial Atrial Fibrillation
Glossitis Heart Disease
Hypertension, Essential Hypothyroidism
Iron Deficiency Anemia Neutropenia
Osteoporosis Paralytic Ileus
Peripheral Vascular Disease Pharyngitis
Pneumocystosis Postinflammatory Pulmonary Fibrosis
Protein-Energy Malnutrition Respiratory Failure
Rheumatoid Arthritis Schizophreniform Disorder
Status Asthmaticus Swallowing Disorders
Vulvovaginal Candidiasis

Graphical network of the top 20 diseases related to Oral Candidiasis:



Diseases related to Oral Candidiasis

Symptoms & Phenotypes for Oral Candidiasis

UMLS symptoms related to Oral Candidiasis:


oral manifestations

GenomeRNAi Phenotypes related to Oral Candidiasis according to GeneCards Suite gene sharing:

25 (show all 22)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased shRNA abundance (Z-score > 2) GR00366-A-105 9.72 DEFB4A
2 Increased shRNA abundance (Z-score > 2) GR00366-A-14 9.72 CD4
3 Increased shRNA abundance (Z-score > 2) GR00366-A-147 9.72 CD4
4 Increased shRNA abundance (Z-score > 2) GR00366-A-148 9.72 DEFA1
5 Increased shRNA abundance (Z-score > 2) GR00366-A-153 9.72 DEFB4A
6 Increased shRNA abundance (Z-score > 2) GR00366-A-160 9.72 CD4
7 Increased shRNA abundance (Z-score > 2) GR00366-A-165 9.72 DEFB4A
8 Increased shRNA abundance (Z-score > 2) GR00366-A-173 9.72 IKBKB
9 Increased shRNA abundance (Z-score > 2) GR00366-A-176 9.72 DEFA1
10 Increased shRNA abundance (Z-score > 2) GR00366-A-178 9.72 DEFA1
11 Increased shRNA abundance (Z-score > 2) GR00366-A-185 9.72 IKBKB
12 Increased shRNA abundance (Z-score > 2) GR00366-A-19 9.72 CD4
13 Increased shRNA abundance (Z-score > 2) GR00366-A-190 9.72 IKBKB
14 Increased shRNA abundance (Z-score > 2) GR00366-A-200 9.72 DEFB4A
15 Increased shRNA abundance (Z-score > 2) GR00366-A-212 9.72 DEFA1
16 Increased shRNA abundance (Z-score > 2) GR00366-A-32 9.72 CD4 DEFA1
17 Increased shRNA abundance (Z-score > 2) GR00366-A-38 9.72 IKBKB
18 Increased shRNA abundance (Z-score > 2) GR00366-A-52 9.72 IKBKB
19 Increased shRNA abundance (Z-score > 2) GR00366-A-54 9.72 DEFA1 DEFB4A IKBKB
20 Increased shRNA abundance (Z-score > 2) GR00366-A-59 9.72 IKBKB
21 Increased shRNA abundance (Z-score > 2) GR00366-A-60 9.72 DEFA1
22 Increased shRNA abundance (Z-score > 2) GR00366-A-85 9.72 IKBKB

MGI Mouse Phenotypes related to Oral Candidiasis:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 immune system MP:0005387 9.89 AIRE APCS B2M CARD9 CCR6 CD4
2 digestive/alimentary MP:0005381 9.76 AIRE B2M CD4 CLEC7A ECE1 IKBKB
3 hematopoietic system MP:0005397 9.55 AIRE APCS B2M CARD9 CCR6 CD4

Drugs & Therapeutics for Oral Candidiasis

PubMed Health treatment related to Oral Candidiasis: 63

Oral thrush can be treated with antimycotics. These are available as drugs that produce either a topical (local) or a systemic (throughout the whole body) effect. Medication that acts in both ways is also an option. The type of medication that is best suited for someone with a weakened immune system will depend on their individual situation.

Drugs for Oral Candidiasis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 141)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Fluticasone Approved, Experimental Phase 4 90566-53-3 4659387 5311101
2
Nystatin Approved, Vet_approved Phase 4 1400-61-9 11953884
3
Amphotericin B Approved, Investigational Phase 4 1397-89-3 5280965
4
Voriconazole Approved Phase 4 137234-62-9 71616
5
Dequalinium Approved, Investigational Phase 4 6707-58-0 2993
6
Terconazole Approved Phase 4 67915-31-5 441383
7
Clindamycin Approved, Vet_approved Phase 4 18323-44-9, 24729-96-2 29029
8
Hydrocortisone succinate Approved Phase 4 2203-97-6 3643
9
Hydrocortisone acetate Approved, Vet_approved Phase 4 50-03-3
10
Hydrocortisone Approved, Vet_approved Phase 4 50-23-7 3640 5754
11
Tinidazole Approved, Investigational Phase 4 19387-91-8 5479
12
Lidocaine Approved, Vet_approved Phase 4 137-58-6 3676
13
Posaconazole Approved, Investigational, Vet_approved Phase 4 171228-49-2 147912
14 Fluticasone-Salmeterol Drug Combination Phase 4
15 Bronchodilator Agents Phase 4
16 Adrenergic beta-Agonists Phase 4
17 Anti-Asthmatic Agents Phase 4
18 Adrenergic Agonists Phase 4
19 Adrenergic Agents Phase 4
20 Neurotransmitter Agents Phase 4
21 Anti-Allergic Agents Phase 4
22 Xhance Phase 4
23 Sympathomimetics Phase 4
24
Salmeterol Xinafoate Phase 4 94749-08-3
25 Anti-Infective Agents, Local Phase 4
26 Cytochrome P-450 CYP3A Inhibitors Phase 4
27 Anti-Bacterial Agents Phase 4
28 Ionophores Phase 4
29 Antiprotozoal Agents Phase 4
30 Antiparasitic Agents Phase 4
31 Liposomal amphotericin B Phase 4
32 Antibiotics, Antitubercular Phase 4
33 Anti-Inflammatory Agents Phase 4
34
Clindamycin phosphate Phase 4 32603
35 Clindamycin palmitate Phase 4
36 Liver Extracts Phase 4
37 Hydrocortisone 17-butyrate 21-propionate Phase 4
38 Acidophilus Phase 4
39 Echinocandins Phase 4
40
Metronidazole Approved Phase 3 443-48-1, 69198-10-3 4173
41
Ketoconazole Approved, Investigational Phase 3 65277-42-1, 142128-57-2 47576 3823 638701
42
Gentian violet cation Approved Phase 3 14426-25-6, 7438-46-2 3468 11057
43
Itraconazole Approved, Investigational Phase 3 84625-61-6 55283
44
Isavuconazole Approved, Investigational Phase 3 241479-67-4 21937662
45
Benzocaine Approved, Investigational Phase 3 1994-09-7, 94-09-7 2337
46
Tannic acid Approved Phase 3 1401-55-4 16129878 16129778
47
Tetracycline Approved, Vet_approved, Withdrawn Phase 3 60-54-8 5353990
48
Simethicone Approved Phase 3 8050-81-5
49
Ibrexafungerp Approved, Investigational Phase 3 1207753-03-4 75163792
50
Levoleucovorin Approved, Experimental, Investigational Phase 3 68538-85-2, 58-05-9, 73951-54-9 149436 6006

Interventional clinical trials:

(show top 50) (show all 272)
# Name Status NCT ID Phase Drugs
1 A Pilot Study to Assess the Incidence of Local Oropharyngeal and Laryngeal Adverse Effects of Advair DISKUS 250/50 Mcg BID as Assessed by the Development of Laryngitis and Oropharyngeal Candidiasis in Adults With Mild Persistent Asthma Unknown status NCT00235053 Phase 4 fluticasone/salmeterol DISKUS 250/50
2 Diagnosis of Pulmonary Candidiasis Unknown status NCT00537888 Phase 4 fluconazole
3 Fluconazole Prophylaxis of Thrush in AIDS Completed NCT00001542 Phase 4 fluconazole
4 Oral Candidiasis in HIV Infected Individuals in Tanzania Completed NCT00553137 Phase 4 fluconazole
5 A Phase IV Randomized Study of the Use of Fluconazole as Chronic Suppressive Therapy Versus Episodic Therapy in HIV Positive Subjects With Recurrent Oropharyngeal Candidiasis Completed NCT00000951 Phase 4 Fluconazole
6 Comparative Study of the Efficacy of 10.0 mg Dequalinium Chloride (Fluomizin®) and 100 mg Clotrimazole (Canesten®) for the Treatment of Vulvovaginal Candidiasis Completed NCT02242695 Phase 4 Fluomizin vaginal tablets;Canesten vaginal tablets
7 CRITIC: Phase II Pilot Multicenter Study on Efficacy and Safety of Liposomal Amphotericin B (AmBisome®) at 2 mg/kg/Day in the Treatment of Candidemia and Invasive Candidiasis in Non-Neutropenic Patients Completed NCT00670657 Phase 4 AmBisome
8 Open-Label, Non-Comparative, Study Of Intravenous Anidulafungin, Followed Optionally By Oral Voriconazole, For Treatment Of Documented Candidemia/Invasive Candidiasis In Hospitalized Patients Completed NCT00548262 Phase 4 Anidulafungin;Voriconazole
9 Epidemiological Study About the Clinical and Microbiological Evolution of Patients Treated for an Acute Episode of Vulvovaginal Candidiasis. Completed NCT02248506 Phase 4
10 A Randomized, Double-blind, Placebo Controlled Trial of Caspofungin Prophylaxis Followed by Pre-emptive Therapy for Invasive Candidiasis in High-risk Adults in the Critical Care Setting Completed NCT00520234 Phase 4 Caspofungin;Normal Saline
11 Phase IV Open Label Non Comparative Trial Of IV Anidulafungin Followed By Oral Azole Therapy For The Treatment Of Candidemia And Invasive Candidiasis Completed NCT00496197 Phase 4 Eraxis (anidulafungin);Diflucan (fluconazole);Vfend (voriconazole)
12 Pharmacokinetics and Optimal Dosage of Caspofungin in Critically Ill Patients With Suspected Invasive Candidiasis Completed NCT01994096 Phase 4 Caspofungin
13 Vaginal Imaging Study to Evaluate the Effect of Exercise on the Distribution of Miconozole Nitrate OVULE Completed NCT00194324 Phase 4 Miconazole nitrate
14 A Randomized, Single-dose, Two-way Crossover Study to Evaluate Bioequivalence of Two Formulations of Micafungin (50 mg/Vial) After Intravenous Infusion of 50 mg Micafungin in Healthy Volunteers Under Fasting Conditions Completed NCT05496725 Phase 4 Micafungin
15 A Randomized, Parallel-group Study of Terconazole Vaginal Suppository vs Fluconazole for the Treatment of Severe Completed NCT02180100 Phase 4 Terconazole Vaginal Suppository;Fluconazole
16 An Case-controlled Randomized Study to the Efficacy of Clotrimazole Vaginal Tablet vs Fluconazole for Severe Vulvovaginal Candidiasis Completed NCT02180828 Phase 4 Clotrimazole vaginal tablet;Fluconazole
17 Pharmacokinetics of Micafungin in Patients of Intensive Care Units Completed NCT02164890 Phase 4
18 Prospective 2-Year Longitudinal Study to Assess for Miconazole Resistance in Candida Spp. With Repeated Treatment Courses of 0.25% Miconazole Nitrate Ointment in Neonates and Infants up to 1 Year of Age With Recurrent Moderate-Severe Diaper Dermatitis Complicated by Cutaneous Candidiasis Completed NCT00702507 Phase 4 0.25 % Miconazole Nitrate Ointment
19 Effectiveness and Safety of Daktacort Feminine Care Cream in the Treatment of Vulvar Candidiasis Completed NCT01769339 Phase 4 Miconazole plus Hydrocortisone
20 A Pilot Study for the Use of Biomarkers and Early Treatment of Invasive Candidiasis in ICU Patients Completed NCT01734525 Phase 4 Anidulafungin
21 Multicenter Pilot Study to Compare the Efficacy of a Combination of Vaginal Capsules With Acid Boric, L.Gasseri and L.Rhamnosus Versus the Reference Medication in Patients With Vaginal Candidiasis or Bacterial Vaginosis Completed NCT02860845 Phase 4 Antibiotic (Clindamycin);Antifungal (Clotrimazole)
22 Fluconazole Pharmacokinetics, Including Bioavailability, in Obese Subjects After an Intravenous and Oral Administration (FOLIA) Completed NCT04122560 Phase 4 Fluconazole 200mg tab;Fluconazole 2 MG/ML
23 An Open Label, Non-comparative, Multicenter Trial of the Efficacy, Safety and Toleration of Voriconazole in the Primary or Secondary Treatment of Invasive Fungal Infection Completed NCT00647907 Phase 4 Voriconazole
24 Invasive Fungal Infection in Liver Transplant Recipients: A Randomized Double-Blind Trial Comparing AmBisome and Fluconazole in the High Risk Group and an Observational Cohort Study in the Low Risk Completed NCT00001107 Phase 4 Fluconazole;AmBisome
25 A National, Multi-central, Open-label, Single-arm, Phase IV Study to Evaluate Efficacy and Safety of Gynomax® XL Ovule in the Treatment of Trichomonal Vaginitis, Bacterial Vaginosis, Candidal Vulvovaginitis and Mixed Vaginal Infections Completed NCT03839875 Phase 4 Gynomax® XL Vaginal Ovule
26 The Role of Oral Nystatin Prophylaxis in ICU Surgical/Trauma Patients Completed NCT01495039 Phase 4 Nystatin
27 Pharmacokinetics Study of Posaconazole in Haematology Patients Receiving Standard of Care Treatment With Oral Posaconazole Prophylaxis for Invasive Fungal Infection Recruiting NCT03717623 Phase 4 Posaconazole pharmacokinetics
28 A Prospective, Case-controlled Randomized Study of Human Reproductive Tract Active Lactobacillus in Adjuvant Treatment of Recurrent Vulvovaginal Candidiasis. Recruiting NCT04699240 Phase 4 clotrimazole vaginal tablets;Clotrimazole vaginal tablets+ Lactobacillus
29 A Randomized Controlled Trial to Compare the Efficacy of a Medical Grade Honey Formulation (L-Mesitran®) and Fluconazol (Diflucan®) for the Treatment of Recurrent Vulvovaginal Candidiasis Not yet recruiting NCT04626258 Phase 4 Fluconazole
30 Multicenter Study to Compare Two Diagnostic Tests (1,3-β-D-glucan vs Blood Culture) in Critically Ill Patients With Suspected Invasive CAndidiasis Hospitalized in Internal Medicine Wards and Who Are Currently Timely Treated With Echinocandin (Micafungin) Terminated NCT03906916 Phase 4 Micafungin
31 A Multi-center, Open-label, Non-comparative Study to Evaluate the Efficacy and Safety of Micafungin Against Invasive Candidiasis or Candidemia (CFDA Commitment) Terminated NCT01982071 Phase 4 Micafungin
32 A Multi-center, Open-label, Non-comparative Study to Evaluate the Safety and Efficacy of Micafungin Against Fungal Infections Caused by Candida Spp or Aspergillus Spp Terminated NCT02646800 Phase 4 Micafungin
33 A Randomized Comparative Study of Fluconazole Versus Micafungin for the Treatment of Candida Bloodstream Infection in Non-Neutropenic Patients Withdrawn NCT00304772 Phase 4 Fluconazole;Micafungin
34 Ketoconazole In Situ Gel Versus Terconazole Cream for Treatment of Vaginal Candidiasis Unknown status NCT03473418 Phase 3 Ketoconazole;Terconazole
35 "A Multi-Centre, Randomized, Double Blind, Parallel-Group, Comparative Clinical Trial to Evaluate the Safety and Clinical Equivalence of Generic Clotrimazole Troche/Lozenges USP, 10mg (Unique Pharmaceutical Laboratories, India) to Clotrimazole Troche/Lozenges ® 10mg (Roxane Laboratories Inc., USA) in Subjects With Oropharyngeal Candidiasis ". Unknown status NCT02635438 Phase 3 Unique Pharmaceutical Laboratories, India;Roxane Laboratories Inc., USA
36 Fluconazole Versus Micafungin in Neonates With Suspected or Culture-proven Candidiasis: a Randomized Pharmacokinetic and Safety Study (TINN Project - Treat Infections iN Neonates) Unknown status NCT02145832 Phase 2, Phase 3 Fluconazole;Micafungin
37 Prospective Multicentre Randomized Double-blind Study Comparing Caspofungin to Placebo for the Treatment of ICU Intra-abdominal Candidiasis Unknown status NCT03580733 Phase 3 caspofungin antifungal therapy
38 Phase III, Open Label, Randomized, Multicenter Study to Evaluate Efficacy, Tolerability & Safety of Combination of Clindamycin 100mg and Ketoconazole 400mg in Vaginal Capsules, Compared to Combination of Tetracycline 100mg and Amphotericin B 50mg in Vaginal Cream for the Treatment of Bacterial Vaginosis and Candidiasis Isolatedly or in Association (Mixed-Type Vaginosis) Unknown status NCT00889356 Phase 3 Clindamycin 100mg and Ketoconazole 400mg;Tetracycline 100mg and Amphotericin B 50mg
39 A Phase 3, Randomized, Double-Blind, Comparative Trial of Two Dosing Regimens of Micafungin (FK463) Versus Caspofungin for the Treatment of Esophageal Candidiasis Completed NCT00665639 Phase 3 micafungin;caspofungin
40 A Phase 3, Randomized, Double-Blind, Comparative Trial of Micafungin Versus Fluconazole for the Treatment of Esophageal Candidiasis Completed NCT00666185 Phase 3 Micafungin;Fluconazole
41 A Comparison of Gentian Violet Mouth Washes, Nystatin Drops and Ketoconazole Tabs in the Treatment of Oropharyngeal Candidiasis Completed NCT00128323 Phase 3 Gentian violet 1% solution;Gentian violet 0.00165% solution;Nystatin solution
42 Randomized, Controlled Trial of SCH 56592 Oral Suspension Versus Fluconazole Suspension in the Treatment of Oropharyngeal Candidiasis (OPC) in HIV-Positive Patients Completed NCT00002446 Phase 3 Posaconazole;Fluconazole
43 A Randomized, Double-Blind, Placebo Controlled Trial Evaluating the Impact of Nystatin on the Development of Oral Irritation in Patients Receiving High Dose Intravenous Interleukin-2 Completed NCT00001812 Phase 3 Nystatin
44 Efficacy of Standardized-propolis Extract (EPP-AF®) Gel Formulation as Buccal Antiseptic in Elderly People Completed NCT02818803 Phase 3 Miconazole
45 A Prospective Randomized, Blinded Parallel Group Study of Clotrimazole Troches vs. Mycelex® Troches (10 mg Troche Five Times a Day for 14 Days) in Patients With Human Insufficiency Virus (HIV) Infection for the Treatment of Oropharyngeal Candidiasis Completed NCT02184351 Phase 3 Roxanes's clotrimazole troches;Mycelex® troches
46 A Non-comparative, Multicenter, Open-label Study to Evaluate the Safety, Tolerability, and Efficacy of Caspofungin Acetate (MK-0991) for the Treatment of Esophageal Candidiasis or Invasive Candidiasis in Chinese Adults Completed NCT00635648 Phase 3 caspofungin acetate
47 Phase 3, Randomized, Double-Blind Study to Evaluate Efficacy and Safety of Oteseconazole (VT-1161) Oral Capsules vs Fluconazole and Placebo in Treatment of Acute Vulvovaginal Candidiasis in Subjects With Recurrent Vulvovaginal Candidiasis Completed NCT03840616 Phase 3 Oteseconazole (VT-1161) 150mg capsule;Fluconazole 150mg capsule;Placebo
48 A Phase III, Double-blind, Randomized Study to Evaluate the Safety and Efficacy of BAL8557 Versus a Caspofungin Followed by Voriconazole Regimen in the Treatment of Candidemia and Other Invasive Candida Infections Completed NCT00413218 Phase 3 Isavuconazole;Caspofungin;Voriconazole
49 Open-Label, Non-Comparative, Study Of Intravenous Anidulafungin, Followed Optionally By Oral Voriconazole Or Fluconazole Therapy, For Treatment Of Documented Candidemia/Invasive Candidiasis In Intensive Care Unit Patient Populations Completed NCT00689338 Phase 3 Anidulafungin;Fluconazole;Voriconazole
50 Study of the Efficacy and Tolerance of Intra-vaginal Treatment With a Total Freeze-dried Culture of Lcr Regenerans® in the Prevention of Relapses of Recurrent Vulvovaginal Candidiasis. International Phase III, Randomised, Multi-centre, Parallel-group, Two Arm, Double-blind Superiority Trial Versus Placebo. Completed NCT02251093 Phase 3 Lcr Regenerans;Placebo

Search NIH Clinical Center for Oral Candidiasis

Inferred drug relations via UMLS 71 / NDF-RT 50 :


Chlorhexidine
chlorhexidine gluconate
Clotrimazole
Fluconazole
Flucytosine
Itraconazole
Ketoconazole
NYSTATIN PWDR

Cochrane evidence based reviews: candidiasis, oral

Genetic Tests for Oral Candidiasis

Anatomical Context for Oral Candidiasis

Organs/tissues related to Oral Candidiasis:

MalaCards : Tongue, Skin, Liver, Myeloid, Bone Marrow, Kidney, Salivary Gland

Publications for Oral Candidiasis

Articles related to Oral Candidiasis:

(show top 50) (show all 3561)
# Title Authors PMID Year
1
Differential expression of secretory aspartyl proteinase genes (SAP1-10) in oral Candida albicans isolates with distinct karyotypes. 53 62
15472333 2004
2
[Development of murine experimental model for candidiasis and its application]. 53 62
15550920 2004
3
Susceptibility of Candida dubliniensis to salivary histatin 3. 53 62
12499171 2003
4
Nonspecific secretory immunity in HIV-infected patients with oral candidiasis. 53 62
12439202 2002
5
Immunohistochemical study on expression of alpha-defensin and beta-defensin-2 in human buccal epithelia with candidiasis. 53 62
11936455 2002
6
Increased serum and salivary immunoglobulins against Candida albicans in HIV-infected patients with oral candidiasis. 53 62
11506465 2001
7
Salivary histatin 5 and human neutrophil defensin 1 kill Candida albicans via shared pathways. 53 62
11083633 2000
8
Complete response of severe, refractory oral candidiasis to mouthwash containing lactoferrin and lysozyme. 53 62
11089630 2000
9
In vivo analysis of secreted aspartyl proteinase expression in human oral candidiasis. 53 62
10225911 1999
10
Predictive value of viral load and other markers for progression to clinical AIDS after CD4+ cell count falls below 200/microL. SEROCO & HEMOCO Study Group. 53 62
9839750 1998
11
Age, gender, and other predictors of the wasting syndrome among HIV-1-infected injecting drug users. 53 62
7742405 1995
12
Decreased plasma concentrations of HDL cholesterol in HIV-infected individuals are associated with immune activation. 53 62
7932082 1994
13
Using serial observations to identify predictors of progression to AIDS in the Toronto Sexual Contact Study. 53 62
1569421 1992
14
A near-complete and time-calibrated phylogeny of the Old World flycatchers, robins and chats (Aves, Muscicapidae). 62
36265831 2023
15
Development, optimization, and evaluation of a nanostructured lipid carrier of sesame oil loaded with miconazole for the treatment of oral candidiasis. 62
35014929 2022
16
In vitro inhibition of a multispecies oral cavity biofilm by Syzygium aromaticum essential oil. 62
34633113 2022
17
Severe congenital neutropenia caused by ELANE gene mutation: A case report and literature review. 62
36343040 2022
18
Distribution and antifungal susceptibility profiles of Candida species isolated from people living with HIV/AIDS in a public hospital in Goiânia, GO, Brazil. 62
36371517 2022
19
The relation between serum levels of interleukin 10 and interferon-gamma with oral candidiasis in type 2 diabetes mellitus patients. 62
36443718 2022
20
Species distribution and susceptibility profiles of oral candidiasis in hematological malignancy and solid tumor patients. 62
36378415 2022
21
Responses of Hermit Thrush (Catharus guttatus) males to conspecific playback with typical and atypical syntactical patterns. 62
36243379 2022
22
Pressure for rapid and accurate mate recognition promotes avian-perceived plumage sexual dichromatism in true thrushes (genus: Turdus). 62
36196886 2022
23
Non-invasive elevation of circulating corticosterone increases the rejection of foreign eggs in female American robins (Turdus migratorius). 62
36395578 2022
24
Current Drug Delivery Strategies for Buccal Cavity Ailments using Mouth Dissolving Wafer Technology: A Comprehensive Review on the Present State of the Art. 62
36443976 2022
25
High-throughput assay for effect screening of amphotericin B and bioactive components on filamentous Candida albicans. 62
35947058 2022
26
Pediatric lichen planus: A single-center retrospective review of 26 patients with follow up. 62
36373243 2022
27
Unexpected Candidal Hyphae in Oral Mucosa Lesions-A Clinico-Pathological Study. 62
36290044 2022
28
Frequency of Candida spp. in the Oral Cavity of Asymptomatic Preschool Mexican Children and Its Association with Nutritional Status. 62
36291446 2022
29
White Tongue Because of Uremic Stomatitis as a Sign of Advanced Kidney Disease. 62
36168856 2022
30
Inferring Therapeutic Targets in Candida albicans and Possible Inhibition through Natural Products: A Binding and Physiological Based Pharmacokinetics Snapshot. 62
36362898 2022
31
Receptor-kinase EGFR-MAPK adaptor proteins mediate the epithelial response to Candida albicans via the cytolytic peptide toxin, candidalysin. 62
36037968 2022
32
Important Roles and Potential Uses of Natural and Synthetic Antimicrobial Peptides (AMPs) in Oral Diseases: Cavity, Periodontal Disease, and Thrush. 62
36278644 2022
33
Palliative Treatment of Esophageal Cancer Using Calcium Electroporation. 62
36358702 2022
34
Bioinformatics analysis to identify intersection genes, associated pathways and therapeutic drugs between COVID-19 and Oral candidiasis. 62
36214307 2022
35
Passerine birds. 62
36283383 2022
36
Impact of enteral immunonutrition on infectious complications and immune and inflammatory markers in cancer patients undergoing chemotherapy: A systematic review of randomised controlled trials. 62
36067585 2022
37
Nystatin Effectiveness in Oral Candidiasis Treatment: A Systematic Review & Meta-Analysis of Clinical Trials. 62
36362833 2022
38
Biofilm formation of Candida isolates from xerostomic post-radiotherapy head and neck cancer patients. 62
35839697 2022
39
In vitro antimicrobial effects of chitosan on microcosm biofilms of oral candidiasis. 62
35914573 2022
40
Multiple Post-SARS-COV2 Infectious Complications in Kidney Transplant Recipient. 62
36295531 2022
41
Curcumin nanoparticles: the topical antimycotic suspension treating oral candidiasis. 62
36100802 2022
42
Oral candidiasis in patients with haematological diseases: Diagnosis through clinical and cytopathological examinations. 62
35603463 2022
43
Comparison between two antimicrobial photodynamic therapy protocols for oral candidiasis in patients undergoing treatment for head and neck cancer: A two-arm, single-blind clinical trial. 62
35772622 2022
44
The Mechanisms of Probiotics, Prebiotics, Synbiotics, and Postbiotics in Oral Cancer Management. 62
36048406 2022
45
Autoimmune Polyglandular Syndrome Type 1: A Report of Rare Case of a 16-Year-Old Asian Female Patient With Respiratory Manifestations. 62
36072782 2022
46
Impact of Antiretroviral Therapy on Oral Health among Children Living with HIV: A Systematic Review and Meta-Analysis. 62
36231240 2022
47
Microplastic accumulation in the gastrointestinal tracts of nestling and adult migratory birds. 62
35577091 2022
48
Genotype-environment associations across spatial scales reveal the importance of putative adaptive genetic variation in divergence. 62
36187181 2022
49
Thidiazuron, a phenyl-urea cytokinin, inhibits ergosterol synthesis and attenuates biofilm formation of Candida albicans. 62
36114903 2022
50
Challenge in the diagnosis, evaluation, and management of burning mouth sensation: A retrospective cohort study. 62
36167586 2022

Variations for Oral Candidiasis

Expression for Oral Candidiasis

Search GEO for disease gene expression data for Oral Candidiasis.

Pathways for Oral Candidiasis

Pathways related to Oral Candidiasis according to GeneCards Suite gene sharing:

(show all 15)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.1 IRF8 IL17RA IL17F IL17A IKBKB CD4
2
Show member pathways
13.05 LTF IRF8 IL17RA IL17F IL17A IKBKB
3 12.28 B2M CARD9 IKBKB IL17A IRF8
4
Show member pathways
12.23 IKBKB CLEC7A CLEC6A CARD9
5
Show member pathways
12.05 IL17RA IL17F IL17A IKBKB
6
Show member pathways
11.89 IL17RA IL17F IL17A IKBKB
7
Show member pathways
11.77 IKBKB CD4 B2M
8
Show member pathways
11.74 LTF HTN3 DEFB4A DEFA1 CD4 CCR6
9
Show member pathways
11.71 IL17F IL17A CD4
10 11.59 IL17A CD4 CCR6
11
Show member pathways
11.59 IL17RA IL17F IL17A IKBKB
12 11.54 IRF8 IL17RA CD4
13
Show member pathways
11.52 IL17RA IL17F IL17A CD4
14 11.3 IL17F IL17A IKBKB CD4
15 10.13 IL17RA IL17A

GO Terms for Oral Candidiasis

Cellular components related to Oral Candidiasis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 external side of plasma membrane GO:0009897 9.4 IL17A ECE1 CLEC6A CD4 CCR6 B2M

Biological processes related to Oral Candidiasis according to GeneCards Suite gene sharing:

(show all 28)
# Name GO ID Score Top Affiliating Genes
1 innate immune response GO:0045087 10.39 APCS CARD9 CLEC6A CLEC7A IKBKB IL17A
2 adaptive immune response GO:0002250 10.32 CARD9 CD4 CLEC6A IL17A IL17F IL17RA
3 immune response GO:0006955 10.25 AIRE B2M CCR6 CD4 CLEC6A DEFA1
4 positive regulation of NF-kappaB transcription factor activity GO:0051092 10.24 LTF IKBKB CLEC7A CARD9
5 defense response to Gram-positive bacterium GO:0050830 10.24 IL17F IL17A DEFB4A DEFA1 CARD9
6 positive regulation of I-kappaB kinase/NF-kappaB signaling GO:0043123 10.23 CARD9 CD4 CLEC6A CLEC7A IKBKB LTF
7 defense response to bacterium GO:0042742 10.21 LTF IRF8 HTN3 DEFB4A DEFA1
8 positive regulation of interleukin-6 production GO:0032755 10.19 IL17RA IL17F IL17A CLEC7A CARD9
9 killing of cells of another organism GO:0031640 10.11 DEFA1 DEFB4A HTN3 LTF
10 positive regulation of interleukin-12 production GO:0032735 10.1 IRF8 IL17A CLEC7A
11 defense response to protozoan GO:0042832 10.08 IRF8 DEFA1 CLEC7A
12 stimulatory C-type lectin receptor signaling pathway GO:0002223 10.04 CLEC6A CLEC7A IKBKB
13 positive regulation of T-helper 17 type immune response GO:2000318 10.03 CLEC7A CLEC6A CARD9
14 defense response to Gram-negative bacterium GO:0050829 10.03 LTF IL17F IL17A DEFB4A DEFA1 CD4
15 interleukin-17-mediated signaling pathway GO:0097400 10 IL17RA IL17F IL17A
16 antifungal innate immune response GO:0061760 9.97 DEFB4A CLEC7A CLEC6A CARD9
17 response to yeast GO:0001878 9.93 CLEC7A CLEC6A
18 negative regulation of viral process GO:0048525 9.93 LTF APCS
19 fibroblast activation GO:0072537 9.91 IL17RA IL17A
20 positive regulation of interleukin-23 production GO:0032747 9.91 IL17RA IL17A CLEC7A
21 detection of yeast GO:0001879 9.89 CLEC6A CLEC7A
22 positive regulation of antimicrobial peptide production GO:0002225 9.88 IL17A IL17F
23 regulation of interleukin-2 production GO:0032663 9.88 CARD9 IL17F
24 disruption of membrane integrity in another organism GO:0051673 9.88 LTF DEFB4A DEFA1
25 positive regulation of chemokine (C-X-C motif) ligand 1 production GO:2000340 9.88 IL17RA IL17F IL17A
26 positive regulation of cytokine production involved in inflammatory response GO:1900017 9.85 CARD9 CLEC7A IL17A IL17F IL17RA
27 immune system process GO:0002376 9.7 LTF IRF8 IL17RA IL17F IL17A CLEC7A
28 defense response to fungus GO:0050832 9.4 IL17RA IL17A HTN3 DEFB4A DEFA1 CLEC6A

Molecular functions related to Oral Candidiasis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein homodimerization activity GO:0042803 9.47 IL17F IL17A IKBKB ECE1 CD4 CARD9

Sources for Oral Candidiasis

2 CDC
6 CNVD
8 Cosmic
9 dbSNP
10 DGIdb
16 EFO
17 ExPASy
18 FMA
19 GARD
27 GO
28 GTR
29 HMDB
30 HPO
31 ICD10
32 ICD10 via Orphanet
33 ICD11
34 ICD9CM
35 IUPHAR
36 LifeMap
38 LOVD
40 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
52 NINDS
53 Novoseek
55 ODiseA
56 OMIM via Orphanet
57 OMIM® (Updated 08-Dec-2022)
61 PubChem
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....